Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | POLG | P54098 | 1/20 | 0.35 |
| ▸ | TK1 | P04183 | 3/20 | 0.34 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67563 | 1.00 | ALB (0.38) | ALBDNMT1ADRB1RNASE1POLG | |
| SCHEMBL12087580 | 1.00 | ALB (0.38) | ALBDNMT1ADRB1RNASE1POLG | |
| SCHEMBL24517423 | 0.90 | RNASE1 (0.46) | ALBDNMT1ADRB1RNASE1TK1 | |
| SCHEMBL18573362 | 0.90 | DNMT1 (0.36) | ALBDNMT1ADRB1RNASE1POLG | |
| SCHEMBL68514 | 0.90 | DNMT1 (0.36) | ALBDNMT1ADRB1RNASE1POLG | |
| SCHEMBL12590058 | 0.90 | DNMT1 (0.36) | ALBDNMT1ADRB1RNASE1POLG | |
| SCHEMBL19884492 | 0.88 | P2RY1 (0.42) | POLGTK1 | |
| SCHEMBL22738250 | 0.87 | ALB (0.39) | ALBDNMT1ADRB1POLGDNMT3B | |
| SCHEMBL12015130 | 0.86 | POLG (0.41) | DNMT1ADRB1POLGTK1DNMT3B | |
| SCHEMBL12087573 | 0.86 | POLG (0.41) | DNMT1ADRB1POLGTK1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
| US-8987226-B2 | Modified single-stranded polynucleotides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-24 | — | — | US | disclosed |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | ALB 3509/4885DNMT1 1952/4885ADRB1 3667/4885 |
| US-20120220649-A1 | MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE | POLM, POLN, PNKP | ALB 4626/4885DNMT1 151/4885ADRB1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.